NO20054631D0 - Antistoff mot tumorspesifikt antigen som mal - Google Patents

Antistoff mot tumorspesifikt antigen som mal

Info

Publication number
NO20054631D0
NO20054631D0 NO20054631A NO20054631A NO20054631D0 NO 20054631 D0 NO20054631 D0 NO 20054631D0 NO 20054631 A NO20054631 A NO 20054631A NO 20054631 A NO20054631 A NO 20054631A NO 20054631 D0 NO20054631 D0 NO 20054631D0
Authority
NO
Norway
Prior art keywords
cancer
template
antibody against
specific antigen
tumor specific
Prior art date
Application number
NO20054631A
Other languages
English (en)
Other versions
NO20054631L (no
Inventor
Shuji Takahashi
Kimihisa Ichikawa
Toshinori Agatsuma
Keisuke Fukuchi
Takehiro Hirai
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO20054631D0 publication Critical patent/NO20054631D0/no
Publication of NO20054631L publication Critical patent/NO20054631L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20054631A 2003-03-10 2005-10-07 Antistoff mot tumorspesifikt antigen som mal NO20054631L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003063648 2003-03-10
PCT/JP2004/003048 WO2004081050A1 (ja) 2003-03-10 2004-03-09 癌特異的抗原を標的とした抗体

Publications (2)

Publication Number Publication Date
NO20054631D0 true NO20054631D0 (no) 2005-10-07
NO20054631L NO20054631L (no) 2005-12-09

Family

ID=32984436

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054631A NO20054631L (no) 2003-03-10 2005-10-07 Antistoff mot tumorspesifikt antigen som mal

Country Status (20)

Country Link
US (4) US7855056B2 (no)
EP (1) EP1602669B1 (no)
JP (1) JP4462964B2 (no)
KR (1) KR20050116374A (no)
CN (2) CN102151334A (no)
AT (1) ATE434044T1 (no)
AU (1) AU2004220182B2 (no)
BR (1) BRPI0408238A (no)
CA (1) CA2518787A1 (no)
DE (1) DE602004021567D1 (no)
DK (1) DK1602669T3 (no)
ES (1) ES2327408T3 (no)
HK (1) HK1078593A1 (no)
MX (1) MXPA05009715A (no)
NO (1) NO20054631L (no)
NZ (1) NZ542220A (no)
RU (1) RU2345090C2 (no)
TW (1) TW200508249A (no)
WO (1) WO2004081050A1 (no)
ZA (1) ZA200507298B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200510282B (en) * 2003-07-02 2007-03-28 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
US20110195396A1 (en) * 2010-02-10 2011-08-11 Selinfreund Richard H Chewable compositions for the stabilization of diagnostic biomarkers
EP2613380B1 (en) 2010-11-05 2015-03-18 LG Chem, Ltd. Enhanced-stability rechargeable battery
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US20140224373A1 (en) * 2013-02-12 2014-08-14 MPS Enterprises, Inc. Lay-flat hose for oilfield hydraulic fracturing operations
BR112017006464A2 (pt) * 2014-10-10 2018-01-30 Innate Pharma bloqueio de cd73
KR102665199B1 (ko) * 2018-11-15 2024-05-14 삼성디스플레이 주식회사 레이저 장치 및 이를 이용한 기판 식각 방법
WO2021072139A1 (en) * 2019-10-11 2021-04-15 Massachusetts Institute Of Technology Formulations for gastrointestinal delivery of oligonucleotides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5728821A (en) 1994-08-04 1998-03-17 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
US5792456A (en) * 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
US6384065B1 (en) 1998-05-08 2002-05-07 Toyama Chemical Co., Ltd. Spiro compounds or salts thereof and preventives/remedies for autoimmune diseases and AP-1 inhibitors containing the same
KR20020047098A (ko) 1999-07-29 2002-06-21 추후제출 ＨＥＲ2/ｎｅｕ에 대한 인간 모노클로날 항체
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US20020172986A1 (en) * 2000-08-21 2002-11-21 Leiby Kevin R. 23228, a novel human tetraspanin family member and uses thereof
US7361343B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20070042360A1 (en) 2001-09-17 2007-02-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003025138A2 (en) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
MXPA04010092A (es) * 2002-04-16 2004-12-13 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7361342B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
ZA200510282B (en) 2003-07-02 2007-03-28 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor

Also Published As

Publication number Publication date
EP1602669B1 (en) 2009-06-17
ATE434044T1 (de) 2009-07-15
MXPA05009715A (es) 2005-10-18
NO20054631L (no) 2005-12-09
US20070025996A1 (en) 2007-02-01
EP1602669A4 (en) 2006-08-09
CN1784426A (zh) 2006-06-07
JP4462964B2 (ja) 2010-05-12
US7361340B2 (en) 2008-04-22
US20080146785A1 (en) 2008-06-19
JP2004290187A (ja) 2004-10-21
NZ542220A (en) 2008-04-30
AU2004220182B2 (en) 2007-12-06
KR20050116374A (ko) 2005-12-12
RU2345090C2 (ru) 2009-01-27
TW200508249A (en) 2005-03-01
CN102151334A (zh) 2011-08-17
DK1602669T3 (da) 2009-09-14
US7741447B2 (en) 2010-06-22
DE602004021567D1 (de) 2009-07-30
CA2518787A1 (en) 2004-09-23
US7855056B2 (en) 2010-12-21
EP1602669A1 (en) 2005-12-07
AU2004220182A1 (en) 2004-09-23
WO2004081050A1 (ja) 2004-09-23
ES2327408T3 (es) 2009-10-29
RU2005128277A (ru) 2006-06-10
US20070166312A1 (en) 2007-07-19
US20060127405A1 (en) 2006-06-15
BRPI0408238A (pt) 2006-03-01
ZA200507298B (en) 2006-06-28
HK1078593A1 (en) 2006-03-17

Similar Documents

Publication Publication Date Title
NO20054631L (no) Antistoff mot tumorspesifikt antigen som mal
WO2003080582A3 (de) Fredericamycin-derivate
DE50310516D1 (de) Fredericamycin-derivate
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
NO20065227L (no) Menoklonale antistoff mot hepatocytt vekstfaktor
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
WO2004075865A3 (en) Selective modulation of tlr-mediated biological activity
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
EA200700225A1 (ru) Аналоги тетрапептида
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
NO20063135L (no) Farmasoytiske preparater og fremgangsmater for insulinbehandling
WO2005062977A3 (en) Prostate cancer specific internalizing human antibodies
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
AR053338A1 (es) Terapia antiproliferativa combinada usando ciertos agentes quimioterapeuticos basados en platino y taxanos
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
NO20072290L (no) Organiske forbindelser.
CY1108395T1 (el) Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
CY1110027T1 (el) Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
DE10342747A1 (de) Pharmazeutischer Wirkstoff gegen Melanome
DE60310975D1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
ATE361097T1 (de) Orale vakzinierung mit dem tumor-antigen-mimotop gln-met-trp-ala-pro-gln-trp-gly-pro-asp
CY1111320T1 (el) Cripto ειδικα αντισωματα

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application